SCIENTIFIC AND INFORMATION-ANALYTICAL MAGAZINE

ISSN 1024-6177 (Print), ISSN 2618-9615 (Online)

JOURNAL DESCRIPTION

The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.

Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.

Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.

The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.

Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.

The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.

Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.

The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.

Issues journals

Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 2. P. 27–33

V.A. Rozhko1, I.V. Veyalkin2, T.M. Sharshakova1

Primary Incidence of Autoimmune Tyroiditis in the Republic of Belarus and Radiation Factor

1 Gomel State Medical University, Gomel, Belarus
2 Republican Scientific and Practical Center of Radiation Medicine and Human Ecology, Gomel, Belarus
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract

Actuality: In the Belarus, the primary incidence of thyroid pathology is in the 2d rank among endocrine diseases after diabetes. Studying the trends in the primary incidence of autoimmune thyroiditis (AIT) in the Belarus is important for improving organizational decisions and further improving the quality of medical care for the population.

Purpose: Is to conduct a comparative analysis of the incidence of AIT in the population and in the affected population based on an epidemiological study in the Belarus, taking into account the radiation and organizational components in the formation of pathology.

Material and methods: The data of the republican statistical reports and the data of the Chernobyl Register from 1997 to 2017 were analyzed. Standard methods of descriptive epidemiology were used in the work.

Results: According to Chernobyl Registry, during the observation period (1997–2017), the primary incidence of AIT decreased by 1.4 times (1997 – 135.1 ± 15.77 0/0000; 2017 – 98.4 ± 7.55 0/0000). The incidence was statistically significantly higher in women than men (ratios ranged from 2.39:1 in 2004 to 4.0:1 in 2000). Moreover, the incidence according to Chernobyl Registry was higher than in the adult population, but in children where was no difference with population data. This indicates a high-quality clinical examination of the children’s population. Two organizational and medical approaches have been formed in the republic. The first approach (Grodno, Brest, Minsk regions and Minsk) is characterized by periods of moderate growth, decline, and growth again. In the second approach (Vitebsk, Mogilev and Gomel regions), there are two periods when the increase in incidence sharply changes to decrease before the end of the study period. An analysis of the odds ratio allowed us to conclude that insignificant effect of radioactive iodine on the incidence of AIT in children at the time of the accident and its absence in the adult population.

Conclusion: The study confirms the importance of the organizational component in the early diagnosis of AIT.

Key words: autoimmune thyroiditis, primary incidence, organizational medical approach, radiation factor, Belarus

For citation: Rozhko VA, Veyalkin IV, Sharshakova TM. Primary Incidence of Autoimmune Tyroiditis in the Republic of Belarus and Radiation Factor. Medical Radiology and Radiation Safety. 2020;65(2):27-33. (In Russ.).

DOI: 10.12737/1024-6177-2020-65-2-27-33

References

1. Biondi B. The Normal TSH Reference Range: What Has Changed in the Last Decade? J Clin Endocrinol Metab. 2013;98(9):3584-7.
2. Nexo MA, Watt T, Pedersen J, Bonnema SJ, Hegedüs L, Rasmussen AK, et al. Increased Risk of Long-Term Sickness Absence, Lower Rate of Return to Work, and Higher Risk of Unemployment and Disability Pensioning for Thyroid Patients: A Danish Register-Based Cohort Study. J Clin Endocrinol Metab. 2014;99:3184-92.
3. Noureldine S. Association of Hashimoto’s thyroiditis and thyroid cancer. Curr Opin Oncol. 2015;27(1):21-5.
4. Pedersen CB. The Danish Civil Registration System. Scand J Public Health. 2011;39(7):22-5.
5. Pedersen J, Bjorner JB, Burr H, Christensen KB. Transitions between sickness absence, work, unemployment, and disability in Denmark 2004-2008. Scand J Work Environ Health. 2012;38(6):516-26.
6. Torimoto K, Okada Y, Nakayamada S, Kubo S, Tanaka Y. Anti-PD-1 antibody therapy induces Hashimoto’s disease with an increase in peripheral blood follicular helper T cells. Thyroid. 2017;27:1335-6.
7. Бронников ВИ, Голырева ТП, Терещенко ИВ. Влияние антропогенных загрязнений на структуру щитовидной железы у жителей Перми. Арх. патологии. 2005(6):18-21. [Bronnikov VI, Golyreva TP, Tereshchenko IV. The influence of anthropogenic pollution on the structure of the thyroid gland in Perm residents. Arch Pathology. 2005(6):18-21. (in Russ.)].
8. Карлович НВ, Мохорт ТВ, Воронцова ТВ. Распространенность и характер аутоиммунной патологии щитовидной железы у лиц молодого возраста с сахарным диабетом типа 1. Пробл. эндокринологии. 2005(1):19-24. [Karlovich NV, Mohort TV, Vorontsova TV. The prevalence and nature of autoimmune thyroid pathology in young people with type 1 diabetes mellitus. Probl Endocrinol. (in Russ.)].
9. Ткач НВ, Парамонова НС, Карева ЕГ. Динамика заболеваемости аутоиммунным тиреоидитом у детей и подростков Гродненской области. Журнал ГГМУ. 2005(3):110-2. [Tkach NV, Paramonova NS, Kareva EG. The dynamics of the incidence of autoimmune thyroiditis in children and adolescents of the Grodno region. Journal of State Medical University. (in Russ.)].
10. Данилова ЛИ. Болезни щитовидной железы и ассоциированные заболевания. Минск-Нагасаки. 2005. 470 с. [Danilova LI. Thyroid Diseases and Associated Diseases. Minsk-Nagasaki. 2005. 470 p. (in Russ.)].
11. Hu S, Rayman MP. Multiple Nutritional Factors and the Risk of Hashimoto’s Thyroiditis. Thyroid. 2017;27(5):597-610.
12. Rugger RM, Trimarchi F, Guiffrida G, et al. Autoimmune comorbidities in Hashimoto’s thyroiditis: different patterns of association in adulthood and childhood/adolescence. Eur J Endocrinology. 2017;176(2):133-41.
13. Кенигсберг ЯЭ, Крюк ЮЕ. Облучение щитовидной железы жителей Беларуси вследствие Чернобыльской аварии: дозы и эффекты. Гомель: РНИУП «Институт радиологии», 2004. 121 с. [Koenigsberg JE, Hook YuE. Irradiation of the thyroid gland of residents of Belarus due to the Chernobyl accident: doses and effects. Gomel: RNIUP Institute of Radiology, 2004. 121 p. (in Russ.)].
14. О порядке организации диспансерного обследования граждан, пострадавших от катастрофы на Чернобыльской АЭС, других радиационных аварий и признании утратившими силу некоторых постановлений Министерства здравоохранения Республики Беларусь и структурного элемента нормативного правового акта: постановление Министерства здравоохранения Республики Беларусь, 16.03.2010 г, № 28. URL: http://pravo.levonevsky.org/bazaby11/republic07/text084.htm (дата обращения 21.02.2020). [On the procedure for organizing a dispensary examination of citizens affected by the Chernobyl disaster, other radiation accidents and invalidating certain decisions of the Ministry of Health of the Republic of Belarus and a structural element of a regulatory legal act: resolution of the Ministry of Health of the Republic of Belarus, March 16, 2010, No. 28 [cited 2020 Feb 21]. Available from: http://pravo.levonevsky.org/bazaby11/republic07/text084.htm (in Russ.)].
15. Об утверждении инструкции о порядке проведения диспансеризации: постановление Министерства здравоохранения Республики Беларусь, 12.08.2016 г. № 96. URL: http://minzdrav.gov.by/upload/dispanserizatsiya/instruktsiya/000127_245033_postan96.pdf (дата обращения 21.02.2020). [On approval of the instructions on the procedure for the medical examination: Decree of the Ministry of Health of the Republic of Belarus, 08.08.2016, No. 96. [cited 2020 Feb 21]. Available from: http://minzdrav.gov.by/upload/dispanserizatsiya/instruktsiya/000127_245033_postan96.pdf (in Russ.)].
16. Моисеев ПИ, Веялкин ИВ, Демидчик ЮЕ. Эпидемиология злокачественных новообразований: принципы и методы. Руководство по онкологии. Учебник. Под ред. О.Г. Суконко. Минск, 2015:51-82. [Moiseev PI, Veyalkin IV, Demidchik YuE. Epidemiology of malignant neoplasms: principles and methods. Guide to oncology: a textbook. Ed OG Sukonko. Minsk, 2015:51-82. (in Russ.)].
17. Breslow NE, Day NE. Statistical methods in cancer research. The design and analysis of cohort studies. Lyon: IARC, 1987;2. 404 p.

PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 26.02.2020.

Accepted for publication: 12.03.2020.

Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 2. P. 34–43

A.S. Abdujapparov, S.I. Tkachev, V.A. Aliev, D.S. Romanov, A.V. Nazarenko, Yu.A. Barsukov, T.N. Borisova, V.V. Glebovskaya

Immediate Results of a Prolonged Course of Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer: a Comparison of Classical and Hypofractional Regimes

N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract

Purpose: To compare the effectiveness of the hypofractional and classical modes of radiation therapy in a neoadjuvant prolonged course of chemoradiotherapy for patients with locally advanced rectal cancer (LARC).

Material and methods: This work is based on a retrospective analysis of the database of patients with LARC, who from 2013 to 2017 underwent a prolonged course of neoadjuvant chemoradiotherapy with subsequent surgical intervention. Patients were divided into two groups: the first (main) group, 71 patients with LARC, who, as part of the neoadjuvant treatment, underwent a course of chemoradiotherapy (CRT) in the hypofractionation mode (4 Gy, 3 fractions per week, 32 Gy to regional lymph nodes pelvis and up to 40 Gy to the primary tumor) in combination with chemotherapy with capecitabine 1650 mg/m2 in two doses daily on weekdays. The second group (control group) included 79 patients with LARC, who underwent CRT in the classical fractionation regimen (2 Gy, 5 fractions per week, 44 Gy to regional pelvic lymph nodes and up to 50–58 Gy to the primary tumor) in combination with capecitabine chemotherapy 1650 mg/m2 in two doses on the days of radiation therapy.

Results: The average duration of a prolonged course of CRT in the main group was 22.56 (95 % CI from 21.94 to 23.18) calendar days, in the control group — 38.84 (95 % CI from 38.12 to 39.54), p = 0.0001. Pathological response of the III degree in the main group was recorded in 23 % of cases, and of the IV degree in 18 %, in the control group these indicators were 19 % and 15 %, respectively, p = 0.4. A decrease in the stage of the tumor process was recorded in 50 (70.4 %) cases in the main group and in 47 (59.5 %) cases in the control group, p = 0.16. No statistically significant differences were observed in the incidence and severity of cases of hematological and local toxicity.

Conclusion: The results of our study confirm that the use of a prolonged course of neoadjuvant chemoradiotherapy in hypofractionation mode does not worsen oncological results, does not increase the frequency and severity of early and late radiation injuries, but at the same time reduces the duration of the course of treatment by two weeks. The hypofractionation regimen can be considered as an alternative and not inferior to the classical regimen in the neoadjuvant course of CRT of patients with LARC.

Key words: neoadjuvant chemoradiotherapy, locally advanced rectal cancer, hypofractional regimen, prolonged course

For citation: Abdujapparov AS, Tkachev SI, Aliev VA, Romanov DS, Nazarenko AV, Barsukov YuA, Borisova TN, Glebovskaya VV. Immediate Results of a Prolonged Course of Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer: a Comparison of Classical and Hypofractional Regimes. Medical Radiology and Radiation Safety. 2020;65(2):34-43. (In Russ.).

DOI: 10.12737/1024-6177-2020-65-2-34-43

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. DOI: 10.3322/caac.21492.
  2. Каприн АД, Старинский ВВ, Петрова ГВ. Злокачественные новообразования в России в 2016 г. (заболеваемость и смертность). Москва. 2018. 250 c. [Kaprin AD, Starinsky VV, Petrova GV. Malignant neoplasms in Russia in 2017 (morbidity and mortality). Moscow: P.A. Herzen MCRI, 2018. 250 p. (in Russ.)].
  3. MacFarlane J, Ryall R, Heald R. Mesorectal excision for rectal cancer. Lancet. 1993;341(8843):457-60. DOI: 10.1016/0140-6736(93)90207-W.
  4. Enker W, Thaler H, Cranor M, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg. 1995;181(4):335-46.
  5. Bosset J, Collette L, Calais G, Mineur L, Maingon P. Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-23. DOI: 10.1056/NEJMoa060829.
  6. Gérard J, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin M, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in t3–4 rectal cancers: results of ffcd 9203. J Clin Oncol. 2006;24(28):4620-5. DOI: 10.1200/JCO.2006.06.7629.
  7. Benson AB 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Mar;15(3):370-98. DOI: 10.6004/jnccn.2017.0036.
  8. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-40. DOI: 10.1056/NEJMoa040694.
  9. Maas M, Nelemans P, Valentini V, Das P, Rödel C, Kuo L, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835-44. DOI: 10.1016/S1470-2045(10)70172-8.
  10. Stipa F, Chessin D, Shia J, Paty P, Weiser M, Temple L, et al. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol. 2006;13(8):1047-53. DOI: 10.1245/ASO.2006.03.053.
  11. Fernandez-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CapOх) compared with induction CapOх followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: grupo cancer de recto 3 study. J Clin Oncol. 2010;28(5):859-65. DOI: 10.1200/JCO.2009.25.8541.
  12. Deutsche Krebsgesellschaft, Deutsche Krebshilfe (Leitlinienprogramm Onkologie). Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.0 AWMF); 2018. http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ (date of request 03.10.2019).
  13. Engstrom PF, Arnoletti JP, Benson AB 3rd, Berlin JD, Berry JM, Chen YJ, et al. NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw. 2010;8:106-20. DOI: 10.6004/jnccn.2010.0007.
  14. Viani GA, Viana BS, Martin JEC, Rossi BT, Zuliani G, Stefano EJ. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial. Cancer. 2016;122:2004-11. DOI: 10.1002/cncr.29983.
  15. Kwak Y-K, Lee S-W, Kay CS, Park HH. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in pelvic radiation therapy with moderate dose. PLoS One. 2017;12:e0183339. DOI: 10.1371/journal.pone.0183339.
  16. Huang C-M, Huang M-Y, Tsai H-L, Huang C-W, Ma C-J, Lin C-H, et al. A retrospective comparison of outcome and toxicity of preoperative image-guided intensity-modulated radiotherapy versus conventional pelvic radiotherapy for locally advanced rectal carcinoma. J Radiat Res. 2017;58:247-59. DOI: 10.1093/jrr/rrw087.
  17. Simson DK, Mitra S, Ahlawat P, Saxena U, Sharma MK, Rawat S, et al. Prospective study of neoadjuvant chemoradiotherapy using intensity-modulated radiotherapy and 5 fluorouracil for locally advanced rectal cancer — toxicities and response assessment. Cancer Manag Res. 2018;10:519-26. DOI: 10.2147/CMAR.S142076.
  18. Benson AB, Venook AP, Al-Hawary MM, Cederquist L, Chen YJ, Ciombor KK, et al. Rectal Cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16:874-901. DOI: 10.6004/jnccn.2018.0061.
  19. Emmertsen KJ, Laurberg S. Bowel dysfunction after treatment for rectal cancer. Acta Oncol. 2008;47:994-1003. DOI: 10.1080/02841860802195251.
  20. Peeters KC, van de Velde CJ, Leer JW, Martijn H, Junggeburt JM, Kranenbarg EK, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients – a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199-206. DOI: 10.1200/JCO.2005.14.779.
  21. Dapper H, Rodríguez I, Münch S, Peeken JC, Borm K, Combs SE, et al. Impact of VMAT-IMRT compared to 3D conformal radiotherapy on anal sphincter dose distribution in neoadjuvant chemoradiation of rectal cancer. Radiat Oncol. 2018;13:237. DOI: 10.1186/s13014-018-1187-7.
  22. Hartley A, Ho KF, McConkey C, Geh JI. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials. The British Institute of Radiology. 2014. DOI: 10.1259/bjr/86650067.
  23. Costi R, Leonardi F, Zanoni D, Violi V, et al. Palliative care and end-stage colorectal cancer management: The surgeon meets the oncologist. World J Gastroenterol. 2014;20:7602-21. DOI: 10.3748/wjg.v20.i24.7602.
  24. Wen G, Zhang J, Chi F, Chen L, Huang S, Niu S. Dosimetric Comparison of Volumetric Modulated Arc Therapy (VMAT), 5F Intensity Modulated Radiotherapy (IMRT) and 3D Conformal Radiotherapy (3DCRT) in Rectal Carcinoma Receiving Neoadjuvant Chemoradiotherapy. Int J Med Phys Clin Eng & Radiat Oncol. 2015;04:54-63. DOI: 10.4236/ijmpcero.2015.41008.
  25. Roh M, Yothers G, O’Connell M, Beart R, Pitot H, Shieldset A, at al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol. 2011;29(15_suppl):3503-3503. DOI: 10.1200/jco.2011.29.15_suppl.3503.
  26. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncology. 2012;13:579-88. DOI: 10.1016/S1470-2045(12)70116-X.
  27. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, et al. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017. July 1;28(suppl_4):iv22–iv40. DOI: 10.1093/annonc/mdx224.
  28. Zhou ZR, Liu SX, Zhang TS, Chen LX, Xia J, Hu ZD, et al. Short-course preoperative radiotherapy with immediate surgery versus long-course chemoradiation with delayed surgery in the treatment of rectal cancer: a systematic review and meta-analysis. Surg Oncol 2014;23(4):211-21. DOI: 10.1016/j.suronc.2014.10.003.
  29. Liu SX, Zhou ZR, Chen LX, Yang YJ, Hu ZD, Zhang TS. Short-course Versus Long-course Preoperative Radiotherapy plus Delayed Surgery in the Treatment of Rectal Cancer: a Meta-analysis. Asian Pac J Cancer Prev 2015;16(14):5755-62. DOI: 10.7314/apjcp.2015.16.14.5755.
  30. Kairevičė L, Latkauskas T, Tamelis A, Petrauskas A, Paužas H, Žvirblis T, et al. Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgery for stage II-III resectable rectal cancer: 5-year survival data of a randomized controlled trial. Medicina (Kaunas) 2017;53(3):150-8. DOI: 10.1016/j.medici.2017.05.006.
  31. Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012;30(31):3827-33. DOI: 10.1200/JCO.2012.42.9597.
  32. Vliegen RF, Beets GL, von Meyenfeldt MF, Kessels AG, Lemaire EE, van Engelshoven JM, et al. Rectal Cancer: MR Imaging in Local Staging — Is Gadolinium-Based Contrast Material Helpful? Radiology. 2005;234(1):179-88. DOI: 10.1148/radiol.2341031403.

PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 28.11.2019.

Accepted for publication: 12.03.2020.

Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 2. P. 50–56

V.P. Pantelkin, V.E. Zhuravleva, A.G. Tsovyanov

Development of Chemical Samples Preparation Method to Reduce the Lower Limit of Absorbed Dose Assessment by Electron Paramagnetic Resonance Spectrometry

A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract

Purpose: Development of a method of chemical sample preparation to reduce the lower limit of the absorbed dose estimation by EPR spectrometry.

Material and methods: The required number of bone samples was prepared to study the effect of chemical treatment of bone material samples in organic solvents on their EPR spectra. They were subjected to primary treatment to separate the bones from the remains of soft biological tissue, then a dense bone was isolated and its defatting was carried out. Further, a series of parallel experiments on chemical treatment of bone materials in solutions of three organic reducing agents (hydrazine hydrate, ethylenediamine and diethylenetriamine) were done to reduce the magnitude of the native signal when carrying out works on reconstruction of absorbed doses using EPR spectroscopy. Recording of EPR spectra was performed on the ELEXSYS E500 Bruker spectrometer equipped with a high-q cylindrical resonator SHQE. Irradiation of the samples was carried out on the X-ray biological unit RUB RUST-M1.

Results: To reduce the lower limit of detection of the absorbed dose and improve the reliability of the assessment of the absorbed dose using the EPR method, it is required to reduce the native component of the EPR signal without affecting, if possible, the radiation component of the EPR signal. To achieve this effect, a chemical treatment in solutions of amines was proposed, which affect the collagen compounds that present in the bones and which are responsible for the appearance of a native signal in the EPR spectrum. After chemical treatment of bone material samples at 30°C for 30 minutes in a solution of different amines, there was a significant decrease in the amplitude of the native signal, which was: 4 for hydrazine hydrate, 3.3 for diethylenetriamine and 2.1 for ethylenediamine. For bone material samples that were subjected to the proposed chemical treatment in hydrazine hydrate, it is possible to confidently determine the amplitude of the radiation signal by a value of 2–3 Gy against the minimum dose values of 6–8 Gy for bone material samples that were not chemically treated.

Conclusion: It was found that during the chemical treatment there is a significant reduction of the native signal in the spectra of EPR of bone materials, the decrease of the radiation signal at the same time was slightly. Comparison of the results of treatment of bone materials in three organic reducing agents showed that the best results are obtained by the use of hydrazine hydrate at a temperature of 30°C for 30 minutes.

Key words: Electron Paramagnetic Resonance, radiation signal, native signal, absorbed dose, bone, chemical treatment

For citation: Pantelkin VP, Zhuravleva VE, Tsovyanov AG. Development of Chemical Samples Preparation Method to Reduce the Lower Limit of Absorbed Dose Assessment by Electron Paramagnetic Resonance Spectrometry. Medical Radiology and Radiation Safety. 2020;65(2):50-6. (In Russ.).

DOI: 10.12737/1024-6177-2020-65-2-50-56

References

1. Местные лучевые поражения. В кн.: Радиационная медицина. Руководство для врачей-исследователей и организаторов здравоохранения. Под ред. Л.А. Ильина. Т. 2. — М.: ИздАт, 2001, С.161-202. [Local Radiation Injuries in: Radiation Medicine. A Guide for Medical Researchers and Health Care Organizers. Ed. by L. A. Ilyin. Vol. 2. — Moscow. IzdAt, 2001:161-202. (in Russ.)].
2. Барабанова АВ, Баранов АЕ, Бушманов АЮ, Гуськова АК. Радиационные поражения человека. Избранные клинические лекции, методическое пособие. Под ред. АЮ Бушманова, ВД Ревы. — Москва. 2007. [Barabanova AV, Baranov AE, Bushmanov AYu, Guskova AK. Radiation damage to humans. Selected clinical lectures, methodological guide. Eds. by AYu Bushmanov, VD Reva. Moscow, 2007. (in Russ.)].
3. Надежина НМ, Галстян ИА, Сачков АВ, Малиновская ИА. Перспективы диагностики и лечения местных лучевых поражений. Медицинская радиология и радиационная безопасность. 2004:49(4):21-8. [Nadezhina NM, Galstyan IA, Sachkov AV, Malinovskaya IA. Prospects for the diagnosis and treatment of local radiation injuries. Medical Radiology and Radiation Safety. 2004:49(4):21-8. (in Russ.)].
4. Галстян ИА, Илевич ЮР, Клещенко ЕД и др. Возможности ретроспективного определения дозы при лучевых поражениях. Медицинская радиология и радиационная безопасность. 2004;49(5):5-13. [Galstyan IA, Ilevich YuR, Kleshchenko ED, et al. Possibilities of retrospective dose estimation in radiation injuries. Medical Radiology and Radiation Safety. 2004;49(5):5-13. (in Russ.)].
5. Надежина НМ, Барабанова АВ, Галстян ИА. Трудности диагностики и лечения пострадавших от воздействия потерянных источников ионизирующего излучения. Медицинская радиология и радиационная безопасность. 2005;50(4):15-20. [Nadezhina NM, Barabanova AV, Galstyan IA. Difficulties in diagnosis and treatment of victims of exposure to lost sources of ionizing radiation. Medical Radiology and Radiation Safety. 2005;50(4):15-20. (in Russ.)].
6. Барабанова АВ. Местные лучевые поражения кожи. Медицинская радиология и радиационная безопасность. 2010;55(5):79-84. [Barabanova AV. Local radiation lesions of the skin. Medical Radiology and Radiation Safety. 2010;55(5):79-84. (in Russ.)].
7. Козицина АН, Иванова АВ, Глазырина ЮА, Цмокалюк АН, Ивойлова АВ, Петров АС. ЭПР-спектроскопия, электрохимические и комбинированные методы анализа. Учеб.-метод. пособие. Под. ред. Ю.А. Глазыриной. Екатеринбург : Изд-во Урал. ун-та, 2018. 60 с. [Kozitsyna AN, Ivanova AV, Glazyrina YA, Tsmokalyuk AN, Ivoylova AV, Petrov AS. EPR spectroscopy, electrochemical and combined methods of analysis. Training manual. Ed. by AYu Glazyrina. Ekaterinburg: publishing House of Ural University, 2018. 60 p. (in Russ.)].
8. Ikeya M. New applications of electron spin resonance: dating, dosimetry and microscopy. Singapore; River Edge: World Scientific, 1993. 500 p.
9. Samoylov AS, Bushmanov AY, Galstyan IA, Nadezhina NA, Pantelkin VP, Aksenenko AV, et al.Local radiolesion in X-ray inspection specialists. Radiation Protection Dosimetry. 2016;171(1):117-20.
10. The Radiological Accident in Lia, Georgia. Vienna: International Atomic Energy Agency, 2014.
11. Fattibene P, Callence F. EPR dosimetry with tooth enamel: A review. Appl Radiat and Isotopes. 2010;68(11):2033-116.
12. Скрипник ДГ. Влияние физико-химической обработки эмали зуба человека на сигнал ЭПР. Автореф. дисс. к.х.н. Обнинск, 2004, 23 с. [Skripnik DG. Effect of physical and chemical treatment of human tooth enamel on the EPR signal. Abstract of thesis for the degree of PhD Chem, Obninsk, 2004, 23 p. (in Russ.)].

PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 17.12.2018.

Accepted for publication: 12.03.2020.

Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 2. P. 44–49

K.Yu. Slashchuk, P.O. Rumyantsev, M.V. Degtyarev, S.S. Serzhenko, O.D. Baranova, A.A. Trukhin, Ya.I. Sirota

Molecular Imaging of Neuroendocrine Tumors by Somatostatin-Receptor Scintigraphy (SPECT/CT) with 99mTc-Tektrotyd

National Medical Research Centre of Endocrinology, Moscow, Russia

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms constituting about 0.5 % of all cancer cases. In recent years, there has been a significant increase in the incidence of NETs, which is primarily due to the active development and improvement of medical imaging technologies. Successful treatment and prognosis for patients with NETs strongly depend on the stage of the disease. One of the effective methods of visualization and staging NETs in nuclear medicine is somatostin receptor scintigraphy (SRS), which is based on the use of partial somatostatin receptor agonists labeled with radioactive isotopes. The article presents an analysis of 55 patients with NETs of various localizations who underwent scintigraphy and SPECT/CT. Radiopharmaceutical was used as a tracer for SRS. It was prepared on the basis of a lyophilisate developed by Polatom (Poland) — Tektrotyd, labeled with 99mTc. According to the results of the study SRS with 99mTc-Tektrotyd is informative in the topical diagnosis of NETs, especially when PET/CT scan with 68Ga-labeled peptides is not available. Sensitivity varies depending on the NET localization. It is necessary to continue researches on the diagnostic value of SRS with 99mTc-Tektrotyd for tumors, in the pathogenesis of which somatostatin receptors play a significant role.

Key words: somatostatin-receptor scintigraphy, SPECT/CT, tektrotyd, octreoscan, neuroendocrine tumors

For citation: Slashchuk KYu, Rumyantsev PO, Degtyarev MV, Serzhenko SS, Baranova OD, Trukhin AA, Sirota YaI. Molecular Imaging of Neuroendocrine Tumors by Somatostatin-Receptor Scintigraphy (SPECT/CT) with 99mTc-Tektrotyd. Medical Radiology and Radiation Safety. 2020;65(2):44-9. (In Russ.).

DOI: 10.12737/1024-6177-2020-65-2-44-49

References

  1. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80 Suppl 1:3-7. DOI: 10.1159/000080731.
  2. Yao JC, Hassan M, Phan A, et al. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063-72. DOI: 10.1200/JCO.2007.15.4377.
  3. Williams E. The Classification of Carcinoid Tumours. Lancet. 1963;281(7275):238-9. DOI: 10.1016/s0140-6736(63)90951-6.
  4. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, et al, editors. WHO classification of tumors of the digestive system. Lyon: IARC; 2010. p. S13-S14.
  5. Tang LH, Basturk O, Sue JJ, Klimstra DS. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Am J Surg Pathol. 2016;40(9):1192-202. DOI: 10.1097/PAS.0000000000000662.
  6. Баранова ОД, Румянцев ПО, Слащук КЮ, Петров ЛО. Радионуклидная визуализация и терапия у пациентов с нейроэндокринными опухолями. Эндокринная хирургия. 2017;11(4):178-90. DOI: 10.14341/serg9572 [Baranova OD, Roumiantsev PO, Slashchuk KY, Petrov LO. Radionuclide imaging and therapy in patients with neuroendocrine tumors. Endocrine Surgery. 2017;11(4):178-90. (in Russ.)].
  7. Kunikowska J, Lewington V, Krolicki L. Optimizing Somatostatin Receptor Imaging in Patients with Neuroendocrine Tumors: The Impact of 99mTc-HYNICTOC SPECT/SPECT/CT Versus 68Ga-DOTATATE PET/CT Upon Clinical Management. Clin Nucl Med. 2017;42(12):905-11. DOI: 10.1097/RLU.0000000000001877.
  8. Czepczyński R, Parisella MG, Kosowicz J, Mikołajczak R, Ziemnicka K, Gryczyńska M, Signore A. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med and Mol Imaging. 2007;34(10):1635-45. DOI: 10.1007/s00259-007-0479-1.
  9. Sergieva S, Robev B, Dimcheva M, Fakirova A, Hristoskova R. Clinical application of SPECT-CT with 99mTc-Tektrotyd in bronchial and thymic neuroendocrine tumors (NETs). Nucl Med Review. 2016;19(2):81-7. DOI: 10.5603/NMR.2016.0017.
  10. Artiko V, Afgan A, Petrovič J, Radovič B, Petrovič N, Vlajković M, Obradović V. Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC. Nucl Med Review. 2016;19(2):99-103. DOI: 10.5603/NMR.2016.0020.
  11. Garai I, Barna S, Nagy G, & Forgács A. Limitations and pitfalls of 99mTc-EDDA/ /HYNIC-TOC (Tektrotyd) scintigraphy. Nucl Med  Review. 2016;19(2):93-8. DOI: 10.5603/NMR.2016.0019.
  12. Al-Chalabi H, Cook A, Ellis C, Patel CN, Scarsbrook AF. Feasibility of a streamlined imaging protocol in technetium-99m-Tektrotyd somatostatin receptor SPECT/CT. Clinical Radiology. 2018;73(6):527-34. DOI: 10.1016/j.crad.2017.12.019.
  13. Briganti V, Cuccurullo V, Di Stasio GD, Mansi, L. (2019). Gamma emitters in pancreatic endocrine tumors imaging in the PET era: is there a clinical space for 99mTc-peptides? Current Radiopharmaceuticals. DOI: 10.2174/1874471012666190301122524.
  14. Boutsikou E, Porpodis K, Chatzipavlidou V, Hardavella G, Gerasimou G, Domvri K, Zarogoulidis K. Predictive Value of 99mTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor Diagnosis. Technology in Cancer Research & Treatment, 2019;18:1-18. DOI: 10.1177/1533033819842586.

PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Informed consent. All patients signed an informed consent to participate in the study.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 18.12.2019.

Accepted for publication: 12.03.2020.

Medical Radiology and Radiation Safety. 2020. Vol. 65. No. 2. P. 57–61

V.V. Fedorov, V.I. Potetnya, A.S. Moiseev, A.E. Chernukha, S.E. Ulyanenko, A.N. Solovev

Mathematical Simulation of the Doses inside Patient Body under Prostate Irradiation with Carbon Ion Beam

A. Tsyb Medical Radiological Research Center — branch of the National Medical Research Radiological Center of the
Ministry of Health of the Russian Federation, Obninsk, Kaluga region
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Abstract

Purpose: The radiotherapy methods using heavy charged particles become popular nowadays due to its high efficiency in treatment of oncological patients. On the other side, the practical application of such particles is deeply connected to the influence of secondary radiation, which is a result of nuclear collisions, that can affect the patients’ tissues and organs outside the treatment field. Doses in the out-of-field volumes should be considered from the standpoint of radiological protection. In this study we perform mathematical simulations of the absorbed dose in various organs under the prostate irradiation with carbon ion beam and compared these dose values with existing reference values from CT procedures, and known radiological protection recommendations against current practice of clinical use of carbon ions.

Material and methods: The simulation tool is general application Monte-Carlo code FLUKA widely used for ionizing radiation transport modeling and simulations in radiological protection field. The patient model is one of the most detailed voxelized anthropomorphic phantom Vishum. During the simulation the absorbed dose of segmented organs has been assessed under the spread-out Bragg peak of carbon ions uniformly covering the prostate with the physical dose. The resulted dose in organs is normalized to the prostate dose. This is the qualitative assessment of radiation treatment procedure which allowed us to analyze the out-of-field doses in distant organs from the viewpoint of radiological protection in ion beam therapy, following existing ICRP Publication 127 guidelines.

Results: The results show that the levels of dose due to prostate irradiation in the regimes widely used in the world practice are two level of magnitude lower than dose levels under the full body CT examination, and are comparable to the aircraft crew doses.

Conclusion: Thus, the obtained results might be interested from the risks assessment point of view, including the secondary radiation-induced cancers or other observable or expected treatment effects.

Key words: Monte-Carlo simulation, ion beam therapy, dose distribution, anthropomorphic phantom, voxel phantom, prostate, secondary radiation, spread-out Bragg peak

For citation: Fedorov VV, Potetnya VI, Moiseev AS, Chernukha AE, Ulyanenko SE, Solovev AN. Mathematical Simulation of the Doses inside Patient Body under Prostate Irradiation with Carbon Ion Beam. Medical Radiology and Radiation Safety. 2020;65(2):57-61. (In Russ.).

DOI: 10.12737/1024-6177-2020-65-2-57-61

References

1. Каприн АД, Ульяненко СЕ. Адронная терапия — точки развития. Медицина: целевые проекты. 2016;23:56-59. [Kaprin AD, Ulyanenko SE. Hadron therapy — development points. Medicine: Target Projects. 2016;23:56-59. (in Russ.)].
2. Соловьев АН, Гулидов ИА, Мардынский ЮС, Ульяненко СЕ и др. Современные тенденции в мире частиц. Краткие итоги конференции PTCOG56. Радиационная биология. Радиоэкология. 2017;57(5):548-50. [Soloviev AN, Gulidov IA, Mardynsky YuS, Ulyanenko SE, Galkin VN, Kaprin AD. Modern Trends in the World of Particles. Summary results of the PTCOG56 Conference. Radiation Biology. Radioecology. 2017;57(5):548-50. (in Russ.)].
3. Durante M, Paganetti H. Nuclear physics in particle therapy: a review. Reports on Progress in Physics. 2016;79:096702 DOI: 10.1088/0034-4885/79/9/096702.
4. Grassberger C, Paganetti H. Elevated LET components in clinical proton beams. Phys Med Biol. 2011;56:6677-91. DOI: 10.1088/0031-9155/56/20/011.
5. Ульяненко СЕ, Лычагин АА, Корякин СН, Чернуха АЕ, и др. Распределение дозы и ЛПЭ в биообъектах при облучении протонами. Медицинская физика. 2018;1(77):68-74. [Ulyanenko SE, Lychagin AA, Koryakin SN, Chernukha AE, Troshina MV, Goulidov IN, et al. Simulation of dose and LET distributions within biological objects in proton fields. Medical Physics. 2018;1(77):68-74. (in Russ.)].
6. Polf JC, Newhauser WD, Titt U. Patient neutron dose equivalent exposures outside of the proton therapy treatment field. Radiat Protect Dosimetry. 2005;115:154-8.
7. Zacharatou J, Lee C, Bolch C, Xu W, Paganetti H. Assessment of organ specific neutron doses in proton therapy using whole-body age-dependent voxel phantoms. Phys Med Biol. 2008;53:693-714. DOI: 10.1088/0031-9155/53/3/012.
8. Корякина ЕВ, Потетня ВИ. Цитогенетические эффекты низких доз нейтронов в клетках млекопитающих. Альманах клинической медицины. 2015;41:72-8. [Koryakina EV, Potetnya VI. Cytogenetic effects of low neutron doses in mammalian cells. Almanac of Clinical Medicine. 2015;41:72-8. (in Russ.)].
9. Gunzert-Marx K, Iwase H, Schardt D, Simon RS. Secondary beam fragments produced by 200 MeV 12C ions in water and their dose contributions in carbon ion radiotherapy. New J Phys. 2008;10:075003. DOI: 10.1088/1367-2630/10/7/075003.
10. Iwase H, Gunzert-Marx K, Haettner E, Schardt D, Gutermuth F, Kraemer M, et al. Experimental and theoretical study of the neutron dose produced by carbon ion therapy beams. Radiat Protect Dosimetry. 2007;126(1-4):615-8.
11. Hultqvist M, Gudowska I. Secondary doses delivered to an anthropomorphic male phantom under prostate irradiation with proton and carbon ion beams Radiat Measurements. 2010;45:1410-3. DOI: 10.1016/j.radmeas.2010.05.020.
12. Hultqvist M, Gudowska I. Secondary absorbed doses from light ion irradiation in anthropomorphic phantoms representing an adult male and a 10 year old child. Phys Med Biol. 2010;55:6633-53. DOI: 10.1088/0031-9155/55/22/004.
13. Xu XG, Bednarz B, Paganetti H. A review of dosimetry studies on external beam radiation treatment with respect to second cancer induction. Phys Med Biol. 2008;53(13):193-241. DOI: 10.1088/0031-9155/53/13/R01.
14. ICRP. Radiological Protection in Ion Beam Radiotherapy. ICRP Publication 127. Annals of the ICRP. 2014;43(4)
15. Zankl M, Fill U, Petoussi-Henss N, Regulla D. Organ dose conversion coefficients for external photon irradiation of male and female voxel models. Phys Med Biol. 2002;47:2367-85.
16. Ballarini F, Battistoni G, Campanella M, Carboni M, Cerutti F, Empl A, et al. The FLUKA code: an overview. J Phys: Conference Series. 2006;41:151-60.
17. Schlattl H, Zankl M, Becker J, Hoeschen C. Dose conversion coefficients for CT examinations of adults with automatic tube current modulation. Phys Med Biol. 2010;55(20):6243-61. DOI: 10.1088/0031-9155/55/20/013.
18. ICRU. Reference Data for the Validation of Doses from Cosmic-Radiation Exposure of Aircraft Crew. ICRU Report 84 (prepared jointly with ICRP). ICRU. 2010;10(2).
19. Osama M, Sishc BJ, Saha J, Pompos A, Rahimi A, Story M, et al. Carbon Ion Radiotherapy: A Review of Clinical Experiences and Preclinical Research, with an Emphasis on DNA Damage/Repair. Cancers. 2017;9(66) DOI: 10.3390/cancers9060066.
20. Антипов ЮМ, Бритвич ГИ, Иванов СВ, Костин МЮ, и др. Формирование поперечно-плоского дозового поля и первые радиобиологические эксперименты на углеродном пучке, выведенном из У-70. Приборы и техника эксперимента. 2015;58(4):107-16. DOI: 10.7868/S0032816215040011 [Antipov YM, Britvich GI, Ivanov SV, Kostin MY, Lebedev OP, Lyudmirskii EA, et al. Transversally-flat dose field formation and primary radiobiological exercises with the carbon beam extracted from the U-70 synchrotron. Instruments and Experimental Techniques. 2015;58(4):552-61. DOI: 10.1134/S0020441215040016. (in Russ.)].
21. Бекетов ЕЕ, Исаева ЕВ, Трошина МВ, Лычагин АА, и др. Результаты предварительных исследований биологической эффективности пучка ионов углерода ускорителя У-70. Радиационная биология. Радиоэкология. 2017;57(5):462-70 [Beketov EE, Isaeva EV, Troshina MV, Lychagin AA, Solovev AN, Koryakin SN, et al. Results of the Preliminary Study on the Evaluation of the Biological Effectiveness of Carbon Ion Beam from U-70 Accelerator. Radiation Biology. Radioecology. 2017;57(5):462-70. DOI: 10.7868/S0869803117050022. (in Russ.)].
22. Каприн АД, Галкин ВН, Жаворонков ЛП, Иванов ВК и др. Синтез фундаментальных и прикладных исследований — основа обеспечения высокого уровня научных результатов и внедрения их в медицинскую практику. Радиация и риск. 2017;26(2):26-40. DOI: 10.21870/0131-3878-2017-26-2-26-40 [Kaprin AD, Galkin VN, Zhavoronkov LP, Ivanov VK, Ivanov SA, Romanko YuS. Synthesis of basic and applied research is the basis of obtaining high-quality findings and translating them into clinical practice. Radiation and Risk. 2017;26(2):26-40. DOI: 10.21870/0131-3878-2017-26-2-26-40. (in Russ.)].

PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 04.02.2019.

Accepted for publication: 12.03.2020.

 

  1. 62-67_Rumiantsev_et_al_eng
  2. 68-81_Narkevich_et_al_eng
  3. 82-86_Ryzhkov_et_al_eng
  4. 87_Commemoration_of_Arutyunyan_eng

Contact Information

 

46, Zhivopisnaya st., 123098, Moscow, Russia Phone: +7 (499) 190-95-51. E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal location

Attendance

4215576
Today
Yesterday
This week
Last week
This month
Last month
For all time
2321
3551
23067
34407
81083
118976
4215576
Forecast today
3456

Your IP:216.73.217.178
Visitor Counter

© Журнал "Медицинская радиология и радиационная безопасность" 2020г.

Яндекс.Метрика

Наверх